Committed to improving patients’ lives

At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients with central nervous system (CNS) disorders.

We recently received FDA approval for NUPLAZIDTM (pimavanserin), the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. We also are developing pimavanserin for Alzheimer’s disease psychosis and schizophrenia—additional areas with severe unmet medical needs. In addition, we have clinical-stage programs for chronic pain and glaucoma.